Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SM-001 in Healthy Adults
NCT05894902Phase 1Unknown
- Sponsor
- AIMS Institute
- Start
- Oct 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of SM-001 in major depressive disorder (MDD) and post-traumatic stress disorder (PTSD) (3 arms), sponsored by AIMS Institute. Primary endpoint: Primary Objective. Status: unknown.
02
Drugs
SM-001
03
Conditions
major depressive disorder (MDD)post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT05894902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05894902.